NASDAQ:ANAB

GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings
······

GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings

A Delaware court dismissed Tesaro’s claim that AnaptysBio anticipatorily breached their Jemperli cancer-drug agreement, preserving Anaptys’ royalty rates. The ruling comes days before GSK’s first-quarter results, with Jemperli sales under scrutiny. Jemperli generated $1.128 billion in 2025 sales, according to Anaptys. The FDA expanded Jemperli’s use in endometrial cancer in 2024.
April 25, 2026

Stock Market Today

  • Hiscox Stock Targets Rise as Analysts Upgrade Fair Value and Capital Returns
    May 26, 2026, 7:41 PM EDT. Analysts have raised the fair value estimate for insurance firm Hiscox (LSE:HSX) from £16.06 to £16.90, with price targets now ranging between £16.11 and £18.00. Morgan Stanley increased its target to £18.00 maintaining an Overweight rating, while RBC Capital raised its target to £17.10 with an Outperform stance. Citi raised its target to £16.11 but kept a Neutral rating, reflecting cautious optimism. The upgrades highlight improved revenue growth assumptions, a higher net profit margin, and a slightly increased price-to-earnings (P/E) ratio forecast. However, the narrower target range suggests limited upside if execution falters. Investors should watch for risks and evolving narratives to gauge Hiscox's potential amid shifting analyst views and capital return strategies.